KRAS and colorectal cancer: In the present study, we focus on extending this established assay platform to genomic DNA extracted from colorectal cancer cell lines to evaluate its applicability to clinically relevant samples, particularly KRAS codon 12 mutations that are associated with tumor progression, treatment resistance, and poor prognosis [31].